UC San Diego Health Researchers Join Pancreatic Cancer “Dream Team”

November 10, 2015

International effort will seek to develop and test new therapies for deadly malignancy —

In an effort to advance research on one of the deadliest forms of cancer, University of California, San Diego School of Medicine researchers Andrew Lowy, MD, and Tannishtha Reya, PhD, have been recruited for their expertise in preclinical modeling, clinical trials and stem cell biology to join a “dream team” of international pancreatic cancer researchers.

The three-year, $12-million effort, sponsored by Stand Up To Cancer, Cancer Research UK and The Lustgarten Foundation, will pursue a three-pronged strategy to better understand and reset so-called “super-enhancers” that may be abnormally active in pancreatic tumors. Super-enhancers are bits of DNA that can cause over-expression of genetic signals, fueling cancer cell growth. … Read the full story from the UC San Diego Newsroom


Tannishtha Reya, PhD, is Professor of Pharmacology in the Skaggs School of Pharmacy and Pharmaceutical Sciences and Professor of Medicine in the University of California, San Diego School of Medicine.

Checkup Diabetes: the Latest Research and Treatments from UC San Diego

News Feature from the UC San Diego Health System Newsroom

Checkup Diabetes: the latest research and treatments at UC San Diego

by Scott LaFee

Diabetes is a monumental public health issue, not just because millions of Americans have been diagnosed with the metabolic disease, but also for the many more millions who either remain undiagnosed or have signs suggesting they will likely become diabetic. .. Read the full news feature from the UC San Diego Health System newsroom

A New Protein Target for Controlling Diabetes

Researchers at the University of California, San Diego School of Medicine have identified a previously unknown biological mechanism involved in the regulation of pancreatic islet beta cells, whose role is to produce and release insulin. The discovery suggests a new therapeutic target for treating dysfunctional beta cells and type 2 diabetes, a disease affecting more than 25 million Americans. … Read the full story from the UCSD Newsroom


Dr. Jerrold OlefskyPrincipal Investigator Jerrold M. Olefsky, MD, is Associate Dean for Scientific Affairs and Distinguished Professor of Medicine in the Division of Endocrinology and Metabolism.

Study report coauthors from the Department of Medicine are Hui Dong, PhD, associate professor of medicine in the Division of Gastroenterology; and Yun Sok Lee, Hidetaka Morinaga, and William Lagakos in the Division of Endocrinology and Metabolism.

Citation for the report: Yun Sok Lee, Hidetaka Morinaga, Jane J. Kim, William Lagakos, Susan Taylor, Malik Keshwani, Guy Perkins, Hui Dong, Ayse G. Kayali, Ian R. Sweet, Jerrold Olefsky. The Fractalkine/CX3CR1 System Regulates β Cell Function and Insulin Secretion. Cell – 11 April 2013 (Vol. 153, Issue 2, pp. 413-425)  |  Read the report summary

Other Recent UCSD News Stories about Dr. Olefsky’s Work